When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ADMS - Adamas Pharma plunges after mixed results in MS trial
Adamas Pharmaceuticals Inc.
"As we did not see the scale of clinical benefit we had hoped for in this study we will fully assess the potential for ADS-5102 in MS patients before determining the extent of our continued investment in this program," says Adamas (ADMS-40.7%) CEO Neil McFarlane after mixed results in the drug's Phase 3 trial.
More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,